Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Clinical trial NCT05954143 · TERMINATED
Trial details
- NCT number
- NCT05954143
- Sponsor
- Bolt Biotherapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-30
- Primary completion
- 2024-09-20
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.